LGND
Ligand Pharmaceuticals IncorporatedHealthcare · $6.3B market cap
Verdict
Share price
$302.96
close of Oct 3, 2026
Fair value
$133.99
Sticker Price
Payback Price
$53.60
buy price
LGND is Overpriced: at $302.96 it trades 126% above its fair value of $133.99. Its buy price (Payback Price) is $53.60, 82% below today's price. Business quality is solid: 3 of 5 key numbers clear the 10% bar.
How we valued it
Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow LGND
Get notified when it reaches its buy price of $53.60. Free.
Create a free accountInsider activity
Since Jun 12, 2026: no open-market purchases, 28 sales worth $18.0M and 14 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Reardon Andrew
CLO & Secretary · 2026-09-03
Sold
$116K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sold
$111K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sold
$606K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sold
$513K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sold
$85K
Show all 28 salesShow fewer
Haas Jason
director · 2026-08-12
Sold
$2.1M
Espinoza Octavio
Chief Financial Officer · 2026-08-12
Sold
$9.2M
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$120K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$289K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$58K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$146K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$103K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$349K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$296K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$45K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$9K
Reardon Andrew
CLO & Secretary · 2026-08-03
Sold
$30K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$190K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$284K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$31K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$219K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$338K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$349K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$32K
Reardon Andrew
CLO & Secretary · 2026-07-01
Sold
$122K
Sabba Stephen L
director · 2026-06-16
Sold
$545K
Haas Jason
director · 2026-06-12
Sold
$886K
Haas Jason
director · 2026-06-12
Sold
$765K
Other filings
Haas Jason
director · 2026-08-12
Option exercise
$316K
Espinoza Octavio
Chief Financial Officer · 2026-08-12
Option exercise
$855K
Espinoza Octavio
Chief Financial Officer · 2026-08-12
Option exercise
$145K
Espinoza Octavio
Chief Financial Officer · 2026-08-12
Option exercise
$160K
Espinoza Octavio
Chief Financial Officer · 2026-08-12
Option exercise
$410K
Show all 14 other filingsShow fewer
Espinoza Octavio
Chief Financial Officer · 2026-08-12
Option exercise
$230K
Reardon Andrew
CLO & Secretary · 2026-08-03
Option exercise
$261K
Reardon Andrew
CLO & Secretary · 2026-07-01
Option exercise
$261K
Davis Todd C
Chief Executive Officer · 2026-06-30
J-Other
$21K
Espinoza Octavio
Chief Financial Officer · 2026-06-30
J-Other
$3K
Reardon Andrew
CLO & Secretary · 2026-06-30
J-Other
$21K
Sabba Stephen L
director · 2026-06-16
Option exercise
$142K
Haas Jason
director · 2026-06-12
Option exercise
$155K
Haas Jason
director · 2026-06-12
Option exercise
$52K
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works